Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the Omicron wave

Ayman Al Jurdi, Leela Morena, Mariesa Cote, Emily Bethea, Jamil Azzi, Leonardo V. Riella
doi: https://doi.org/10.1101/2022.05.17.22274980

Article usage

Article usage: May 2022 to August 2025

AbstractFullPdf
May 20221920131732
Jun 2022132965524
Jul 202273574233
Aug 202252111193
Sep 20223705113
Oct 2022262472
Nov 2022234272
Dec 2022130244
Jan 2023109223
Feb 202373418
Mar 20236238
Apr 202342111
May 20232118
Jun 20232557
Jul 20233612
Aug 202318126
Sep 20232169
Oct 20232756
Nov 20231780
Dec 20232634
Jan 2024942
Feb 20241913
Mar 20241597
Apr 2024719
May 2024613
Jun 20241777
Jul 202412211
Aug 20241758
Sep 20242227
Oct 20241074
Nov 202411410
Dec 20248210
Jan 202516412
Feb 202518813
Mar 202527911
Apr 202519012
May 202520715
Jun 202522154
Jul 2025161614
Aug 2025102
Back to top
Posted May 17, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the Omicron wave
Ayman Al Jurdi, Leela Morena, Mariesa Cote, Emily Bethea, Jamil Azzi, Leonardo V. Riella
medRxiv 2022.05.17.22274980; doi: https://doi.org/10.1101/2022.05.17.22274980
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area